Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study
Open Forum Infectious Diseases · 23.12.2024 · 12 (1)
DOI: 10.1093/ofid/ofaf006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 08.01.2025. Verfasst von Léopold Beeker und 28 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Establishing correlates of protection often requires large cohorts. A rapid and adaptable case–control study design can be used to identify antibody correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in serum and saliva.
Methods
We designed a case–control study to compare antibody levels between cases of SARS-CoV-2 infection within 5 days of symptom onset and uninfected controls. Controls were matched on age, number of coronavirus disease 2019 vaccine doses, time since last dose, and past episodes of infection. We quantified anti-SARS-CoV-2 and seasonal coronavirus immunoglobulin (Ig) G in serum and saliva at inclusion, 1 month, and 6 months.
Results
We included 90 cases and 62 controls between February and September 2022. A boost and decay pattern of serum antibodies was observed in cases at 1 and 6 months, respectively, but not in controls. Anti-SARS-CoV-2 antibody levels were significantly higher in controls at inclusion both in serum (particularly antinucleocapsid IgG: 4.14 times higher compared with cases; 95% CI, 2.46–6.96) and saliva (particularly antispike for Delta variant IgG: 4.89 times higher compared with cases; 95% CI, 2.91–9.89). Saliva antibodies generally outperformed serum antibodies for case/control differentiation.
Conclusions
In this case–control study, we provided evidence of correlates of protection of anti-SARS-CoV-2 IgG in saliva and serum, with saliva antibodies often outperforming serum. The finding that antibodies in saliva are a better correlate of protection than antibodies in serum may inform vaccine development by highlighting the importance of robust induction of mucosal immune responses. This study design may be used during future epidemics for the prompt assessment of correlates of protection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.
- Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.
- Hub de Bioinformatique et Biostatistique, Institut Pasteur, Université Paris-Cité, Paris, France.
- Plateforme d'Investigation Clinique (ICAReB-Clin), Institut Pasteur, Université Paris-Cité, Paris, France.
- Biobanque de Collections de Ressources Biologiques d'Origine Humaine (ICAReB-Biobank), Center for Translational Science, Institut Pasteur, Université Paris-Cité, Paris, France.
- Pôle de Coordination de la Recherche Clinique (PC-RC), Institut Pasteur, Université Paris-Cité, Paris, France.
ORCID-Profile: Léopold Beeker, Laura Garcia
Zitieren
APA
Beeker, L., Obadia, T., Bloch, E., Garcia, L., Le Fol, M., Charmet, T., Arowas, L., Artus, R., Cheny, O., Cheval, D., Dahoumane, Y., Delhaye, M., Ergen, D., Essaidani, M., Fanaud, C., Fernandes Pellerin, S., Jolly, N., Laude, H., Roux, E., …, & White, M. (2024). Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study. Open Forum Infectious Diseases, 12(1). https://doi.org/10.1093/ofid/ofaf006
Vancouver
Beeker L, Obadia T, Bloch E, Garcia L, Le Fol M, Charmet T, et al. Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study. Open Forum Infectious Diseases. 2024;12(1). doi:10.1093/ofid/ofaf006
BibTeX
@article{Beeker2024,
author = {Beeker, Léopold and Obadia, Thomas and Bloch, Emma and Garcia, Laura and Le Fol, Manon and Charmet, Tiffany and Arowas, Laurence and Artus, Rémy and Cheny, Olivia and Cheval, Dorian and Dahoumane, Yanis and Delhaye, Maurine and Ergen, Delal and Essaidani, Mariem and Fanaud, Christine and Fernandes Pellerin, Sandrine and Jolly, Nathalie and Laude, Hélène and Roux, Emmanuel and Samson, Marine and Sangari, Linda and Ungeheuer, Marie-Noëlle and Vacant, Sophie and Zayoud, Ayla and Donnadieu, Françoise and Pelleau, Stéphane and Galmiche, Simon and Fontanet, Arnaud and White, Michael},
title = {Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case–Control Study},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {12},
number = {1},
doi = {10.1093/ofid/ofaf006}
}
EUVIMED